Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796470 | 1.00 | HTT (0.53) | HTTCYP1A2CYP2C19ALDH1A1DYRK1A | |
| SCHEMBL29470857 | 0.81 | DYRK1A (0.52) | HTTCYP1A2CYP2C19ALDH1A1DYRK1A | |
| SCHEMBL934055 | 0.81 | DYRK1A (0.52) | HTTCYP1A2CYP2C19ALDH1A1DYRK1A | |
| Quinoline SCHEMBL28218277 | 0.80 | ALDH1A1 (0.63) | HTTCYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL25195755 | 0.78 | KDM4E (0.61) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL274826 | 0.76 | ALDH1A1 (0.44) | HTTCYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL8194 | 0.75 | ALDH1A1 (0.67) | HTTCYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL30099834 | 0.75 | ALDH1A1 (0.67) | HTTCYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL19445102 | 0.74 | ALDH1A1 (0.43) | HTTCYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL4141544 | 0.74 | BCHE (0.44) | HTTCYP1A2CYP2C19ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109698-A1 | MALT-1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250051327-A1 | MALT-1 MODULATORS | RECURSION PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024258154-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 진웅산업 | 2024-12-19 | — | — | WO | disclosed |
| WO-2024258158-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | 주식회사 진웅산업 | 2024-12-19 | — | — | WO | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008082487-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| CN-101035780-A | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | MERCK SHARP & DOHME (GB) | 2007-09-12 | — | — | CN | disclosed |
| US-20060148730-A1 | Using macrolide and ketolide compound | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-07-06 | — | — | US | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
| US-20050014706-A1 | Method of treating tuberculosis | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2005-01-20 | — | — | US | disclosed |
| EP-1345953-A2 | KETOLIDE ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6590083-B1 | Compounds of given formula; erythromycin derivatives; useful in the treatment of bacterial and protozoal infections and conditions involving gastric motility | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-08 | — | — | US | disclosed |
| WO-2002032918-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148730-A1 | Using macrolide and ketolide compound | MLYCD, TREH, TKT | HTT 3582/4885CYP1A2 2749/4885CYP2C19 1661/4885 |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | HTT 1490/4885CYP1A2 1165/4885CYP2C19 1781/4885 |
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | HTT 123/4885CYP1A2 502/4885CYP2C19 629/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | HTT 397/4885CYP1A2 2414/4885CYP2C19 2945/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | HTT 234/4885CYP1A2 3256/4885CYP2C19 3974/4885 |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | HTT 1273/4885CYP1A2 2686/4885CYP2C19 4054/4885 |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP9, DPP7, DPP4 | HTT 3592/4885CYP1A2 1328/4885CYP2C19 1109/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | HTT 397/4885CYP1A2 2414/4885CYP2C19 2945/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | HTT 278/4885CYP1A2 2366/4885CYP2C19 2594/4885 |
| US-20050014706-A1 | Method of treating tuberculosis | TREH, TKT, DCXR | HTT 3560/4885CYP1A2 1257/4885CYP2C19 1166/4885 |
| US-20250051327-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL9 | HTT 3492/4885CYP1A2 2312/4885CYP2C19 3333/4885 |
| US-20260109698-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL3 | HTT 2522/4885CYP1A2 2389/4885CYP2C19 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.